> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Tpoxx Smallpox Drug
- URL: https://www.fdaweb.com/review-period-set-for-tpoxx-smallpox-drug/
- Published: 2021-04-01T12:00:00.000Z
- Updated: 2026-09-14T16:53:22.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149016

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Siga Technologies’ Tpoxx (tecovirimat monohydrate), indicated for treating human smallpox disease in adults and pediatric patients weighing at least 13kg. The review period was determined to be 4,601 days, which includes 4,383 days that occurred during the testing phase and 218 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06696.pdf?ref=fdaweb.com).